REG - BiVictriX Therapcts. - BiVictriX: Board Change

Bivictrix TherapeuticsAnnouncement

06/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230106:nRSF8691La&default-theme=true

RNS Number : 8691L  BiVictriX Therapeutics PLC  06 January 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company" or the "Group")

Board Change

Dr. Michael Kauffman, M.D., Ph.D. appointed as Non-Executive Chairman

Iain Ross to remain a Board member

Alderley Park, 6 January 2023 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, announces that Dr. Michael Kauffman, M.D., Ph.D. has been
appointed as Non-Executive Chairman. Dr Kauffman takes over from Iain Ross,
who will continue as a Non-Executive Director on the BiVictriX Board, but
steps down as Chairman due to other work commitments.

Prior to becoming Non-Executive Chairman, Dr. Kauffman was appointed as
Non-Executive Director of BiVictriX in January 2022. He is a highly
experienced cancer drug developer, having been instrumental in the approval of
several oncology therapeutics over twenty years of working across preclinical
research, clinical development, regulatory strategy and commercialisation. As
Non-Executive Chairman, he will draw upon his previous experience as
Co-Founder and Chief Executive Officer of oncology company Karyopharm
Therapeutics Inc., which he guided from a discovery stage biotechnology
company to a commercial stage organisation, with global approvals of XPOVIO®.
He also led the Kyprolis® development programme at Proteolix and then Onyx
Pharmaceuticals, the Velcade® development programme at Millennium
Pharmaceuticals, and has held a number of senior positions at Millennium
Predictive Medicine and Biogen. Dr Kauffman currently holds other
Non-Executive Board positions at Verastem Oncology, Adicet Bio and Kezar Life
Sciences.

Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc,
commented: "With the recent identification of our lead candidate, the
transition of Michael Kauffman to Non-Executive Chairman of the Board comes at
a pivotal time in BiVictriX's development. I am delighted to welcome Michael
to his new role; no doubt his wealth of expertise across oncology drug
development will continue to prove invaluable during the next stage of our
progression. I would like to also express gratitude on behalf of the whole
Company to Iain for his excellent support, taking us through from IPO to
candidate identification and look forward to continuing to work alongside him
as a valued member of our Board."

Dr. Michael Kauffman, Non-Executive Chairman of BiVictriX, added: "Having been
a member of BiVictriX's Board over the past year, I have witnessed the
Company's remarkable progress and am excited to step up to Chairman at this
stage of the Company's development. The Bi-Cygni® platform is designed to
optimise the potential of ADCs by reducing off target-binding associated with
toxicities and increasing tumor-selective killing. I am looking forward to
BiVictriX progressing BVX001 into the clinic, where we hope to be
differentiated by our delivery of key outcomes in cancer-selective therapies
for the support of patients who currently have limited options."

 

Iain Ross,  Non-Executive Director at BiVictriX, commented: "It has been a
privilege to have chaired the BiVictriX Board over the past couple of years
and to have seen it grow into such a strong position. I am now, as a result of
additional responsibilities at ReNeuron Group plc, handing over the reins to
Michael, who is well experienced to support the Company as Chairman as it
enters its next stage of pipeline development. I look forward to remaining
actively involved in BiVictriX as a Non-Executive Director."

 

For more information, please contact:

 BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Michael Kauffman, Non-Executive Chairman                         Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)                Tel: +44 (0) 20 3470 0470
 David Hignell, Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon  (UK) Limited (Joint Broker)                      Tel: +44 (0) 20 7886 2500
 Rupert Dearden, Freddy Crossley, Emma Earl

 Consilium Strategic Communications

 Mary-Jane Elliott, Namrata Taak, Genevieve Wilson, Alex Gunter   Tel: +44 (0) 20 3709 5700

                                                                  Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a new class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related harmful side effects.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
cancer-specific antigen pairs, or "twin antigens fingerprints", on tumour
cells, which are largely absent from healthy cells. Whereas this concept has
been validated in a clinical diagnostic setting to support the diagnosis and
monitoring of haematological cancers, it has not yet been widely used in a
therapeutic setting, where it offers the opportunity to be a game-changing
approach to cancer care.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens fingerprints" across a broad range of cancer indications. The Company
is using these novel twin antigens to develop more effective and safer
therapeutics to target cancers that are expected to constitute orphan
indications and areas of high unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASSLESIEDSEIF